AZD7687 Multiple Ascending Dose Study

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Obese; Overweight

Treatments: Drug: Placebo; Drug: AZD7687

Study type: Interventional

Funder types: Industry

Identifiers

NCT01119352

D2710C00002

2010-019112-21 (EudraCT Number)

Details and patient eligibility

About

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects

Enrollment: 45 patients

Sex: All

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of signed and dated, written informed consent prior to any study specific procedures
• suitable veins for cannulation or repeated venepuncture.
• Have a body mass index (BMI) between 27 and 35 kg/m2

Exclusion criteria

• Fasting serum (S)-glucose ≥7.0 mmol/L or non-fasting S-glucose ≥11.1 mmol/L at screening.
• Any eating disorder or actively attempting to loose weight within 3 months prior to enrolment.
• Smoking more than 7 cigarettes per week from time of consent

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

45 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD7687

2

Placebo Comparator group

Treatment:

Drug: Placebo